Jagsonpal Pharmaceuticals Ltd
JAGSNPHARM NSE
Jagsonpal Pharmaceuticals Ltd
HealthcareNSE: JAGSNPHARM BSE: 507789 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹1,617 Cr
Volatility
Moderate
P/E Ratio
35.67
EBITDA
₹56.00 Cr
Return on Equity
23.07%
Debt to Equity
0.03
Book Value
₹41.86
EPS
₹8.61
52W High
₹264.5
52W Low
₹155
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jagsonpal Pharmaceuticals Ltd insights
43 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
4- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 50.3%
- Promoter holding has increased by 1.17% over last quarter.
- Company's working capital requirements have reduced from 24.0 days to 11.0 days
Weaknesses
1- The company has delivered a poor sales growth of 8.85% over past five years.
Growth Rate
Revenue Growth
3.73% ↘
Net Income Growth
-19.98% ↘
Cash Flow Change
57.24% ↗
ROE
92.41% ↗
ROCE
81.03% ↗
EBITDA Margin (Avg.)
-12.57% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 | 73 | 64 | 82 |
| Expenses | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 | 57 | 53 | 65 |
| Operating Profit | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 | 16 | 11 | 17 |
| OPM % | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% | 22% | 22% | 17% | 21% |
| Other Income | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 | 1 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| PBT | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 | 15 | 12 | 18 |
| Tax % | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 | 11 | 9 | 13 |
| EPS in Rs | 1.14 | 1.14 | 0.6 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 | 1.64 | 1.31 | 2 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 287 | 294 |
| Expenses | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 229 | 233 |
| Operating Profit | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 58 | 61 |
| OPM % | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% | 21% |
| Other Income | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 10 | 10 |
| Interest | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 | 9 |
| PBT | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 58 | 61 |
| Tax % | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | 25% | — |
| Net Profit | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 43 | 45 |
| EPS in Rs | 0.18 | 0.5 | 1.81 | -1.76 | 1.1 | 1.2 | 2.6 | 2.88 | 4.08 | 3.4 | 8.34 | 6.43 | 6.84 |
| Div. Payout % | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% | 62% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 263 |
| Borrowings | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 8 |
| Other Liabilities | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 32 |
| Total Liabilities | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
| Fixed Assets | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 85 |
| CWIP | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other Assets | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 231 |
| Total Assets | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 317 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 9 | -3 | -2 | 31 | 11 | 28 | 7 | 47 | 35 | 55 | 47 |
| Investing | 0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 | -36 |
| Financing | -1 | -6 | -34 | -1 | -6 | -1 | -7 | -18 | 0 | -9 | -12 | -12 |
| Net Cash Flow | 2 | 1 | 5 | -6 | 24 | 0 | 19 | -36 | -11 | 2 | -2 | -1 |
| Free Cash Flow | 4 | 6 | 40 | -5 | 30 | 12 | 28 | 6 | 48 | 35 | 91 | 47 |
| CFO/OP | 53 | 83 | -6 | 14 | 311 | 150 | 164 | 54 | 158 | 189 | 124 | 101 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 | 22 |
| Inventory Days | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 | 51 |
| Days Payable | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 | 40 |
| Cash Conversion Cycle | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 | 33 |
| Working Capital Days | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 | 11 |
| ROCE % | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% | 23% |
Documents
1
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 May - Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company 7 May - Newspaper Publication regarding dispatch of Letter of Offer of Buy Back to the shareholders of the Company
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
28 Apr - Audio recording of Q4 FY26 earnings call held April 28, 2026 is available on the company website. 28 Apr - Audio recording of Q4 FY26 earnings call held April 28, 2026 is available on the company website.
3
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Apr - Submission of Public Announcement pertaining to Buy back of Shares of Company published in the newspaper along with Board and Shareholder Resolution 29 Apr - Submission of Public Announcement pertaining to Buy back of Shares of Company published in the newspaper along with Board and Shareholder Resolution
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 Apr - Newspaper Advertisement- Extract of Audited Financial Results for FY 26 29 Apr - Newspaper Advertisement- Extract of Audited Financial Results for FY 26
5
Submission Of Letter Of Offer For Buy-Back Upto 16,00,000 Equity Shares
6 May - Jagsonpal launches 16 lakh share buyback at ₹250 each, totaling up to ₹40 crore; opens May 8, 2026. 6 May - Jagsonpal launches 16 lakh share buyback at ₹250 each, totaling up to ₹40 crore; opens May 8, 2026.
Frequently Asked Questions about Jagsonpal Pharmaceuticals Ltd
What does Jagsonpal Pharmaceuticals Ltd do?
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Where is Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) listed?
Jagsonpal Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: JAGSNPHARM and BSE: 507789. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Jagsonpal Pharmaceuticals Ltd belong to?
Jagsonpal Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has a market capitalisation of approximately ₹1616.85 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Jagsonpal Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Jagsonpal Pharmaceuticals Ltd is 35.67. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Jagsonpal Pharmaceuticals Ltd?
Over the past 52 weeks, Jagsonpal Pharmaceuticals Ltd has traded between a low of ₹155 and a high of ₹264.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Jagsonpal Pharmaceuticals Ltd pay dividends?
Yes, Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.69%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd has a Return on Equity (ROE) of 23.07%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Jagsonpal Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Jagsonpal Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Website jagsonpal.com
CEO Mr. Manish Gupta
Employees 1,399
Listed 2000-03-01
Face Value ₹ 2
Issued Size 6,67,81,270